Investigation of Hemodynamics and Radiomics Based on High Resolution Magnetic Resonance Imaging f… (NCT07335029) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
Investigation of Hemodynamics and Radiomics Based on High Resolution Magnetic Resonance Imaging for Predicting the Outcomes of Intracranial Dissecting Aneurysm
China208 participantsStarted 2023-01-01
Plain-language summary
This study aims to conduct a comprehensive analysis by integrating clinical factors, aneurysm morphological characteristics, and factors reflecting pathophysiological processes (such as hemodynamic and radiomics features), in order to explore the hemodynamic mechanisms associated with the progression of intracranial dissecting aneurysms. Furthermore, artificial intelligence algorithms will be employed to develop and validate an intelligent risk prediction model for the progression and outcomes of intracranial dissecting aneurysms.
Who can participate
Age range
18 Years – 80 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Intracranial dissecting aneurysm clearly diagnosed by DSA and high-resolution MRI imaging (according to the imaging diagnostic criteria proposed in the Chinese Expert Consensus on Imaging Diagnosis of Intracranial Arterial Dissection)
. patients managed with conservative treatment and follow-up
. patients who agree and sign a written informed consent form
Exclusion criteria
. Arteritis, fibromuscular dysplasia, iatrogenic or traumatic pseudoaneurysms
. Contraindications to MRI examination (such as claustrophobia or metallic implants), or contraindications to cerebral angiography (such as iodine contrast allergy)
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Progression of intracranial dissecting aneurysms
Timeframe: From enrollment to 12 months of follow-up
. Dissecting aneurysms extending from the extracranial segment to the intracranial segment, or cases with concomitant intracranial atherosclerotic plaques in the affected vessels
. Patients who refuse MRI examination
. Patients with severe comorbid diseases and an expected survival time of less than 2 years due to these conditions
. Patients without follow-up HR-MRI imaging for any reason